secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001213900-23-025506
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences reports FY2022 net loss of $10.6M; going concern doubt raised
--------------------------------------------------------------------------------

- Net revenues $18.4M, down 10.7% from $20.6M in 2021; operating loss widened to $6.6M from $6.1M.
- Net loss attributable to common stockholders $10.6M ($0.21 per share) vs $15.9M ($0.32) in 2021.
- Cash and cash equivalents $2.0M at Dec 31, 2022, down from $2.3M; substantial doubt about going concern.
- Audit report includes going-concern qualification; company cites Covid disruptions and higher distributor discounts.
- Marketing authorizations for Endari obtained in Qatar, Kuwait, and UAE in 2022; management cites strong sales momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/0001213900-23-025506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/ea176042-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-025506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer